Literature DB >> 27003787

Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease.

Yaping Chu1, Gerardo A Morfini2, Jeffrey H Kordower1.   

Abstract

BACKGROUND: Activity-dependent neuroprotective protein (ADNP) is essential for brain formation and neuronal survival. It is possible that intracellular alpha-synuclein (α-syn) inclusions may be due to, or may cause, down-regulation of ADNP expression.
OBJECTIVE: This study were to determine whether ADNP protein levels are altered in nigral dopaminergic neurons, establish whether ADNP alterations are associated with α-syn accumulation, and evaluate potential correlations between levels of ADNP expression and axonal transport motor proteins in sporadic and experimental Parkinson's disease (PD).
METHODS: Twenty human brains from PD (n = 12) and age-matched controls (n = 8) and sixteen rat brains received α-synuclein gene (n = 8) or empty vector (n = 8) were analyzed using immunohistochemistry. The number of ADNP labeled nigral neurons were estimated with stereology and the levels of ADNP were determined using densitometry.
RESULTS: Compared to age-matched controls, a marked reduction in ADNP protein levels was observed in neuromelanin-containing nigral neurons of PD. Reduced ADNP levels did no relate to the progression of PD symptoms, but instead occurred at early PD stages, before reductions in tyrosine hydroxylase could be detected. Reductions in ADNP were also positively correlated with alterations in axonal transport motor protein. Reductions in ADNP levels were recapitulated in a rat model of PD based on viral over-expression of human wild-type α-synuclein, suggesting that ADNP reductions in PD are a direct result of α-synuclein overexpression.
CONCLUSION: These findings demonstrate that the down-regulation of protein ADNP is an early pathological alteration and may contribute to dopaminergic neurodegeneration in PD.

Entities:  

Keywords:  Activity-dependent neuroprotective protein; Parkinson’s disease; axonal transport; synucleinopathy

Mesh:

Substances:

Year:  2016        PMID: 27003787     DOI: 10.3233/JPD-160812

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  4 in total

1.  ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

Authors:  Y Ivashko-Pachima; C Laura Sayas; A Malishkevich; I Gozes
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

2.  Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP.

Authors:  Yanina Ivashko-Pachima; Kim B Seroogy; Yehonatan Sharabi; Illana Gozes
Journal:  J Mol Neurosci       Date:  2021-07-21       Impact factor: 3.444

3.  Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond.

Authors:  Oxana Kapitansky; Eliezer Giladi; Iman Jaljuli; Stefan Bereswill; Markus M Heimesaat; Illana Gozes
Journal:  J Neural Transm (Vienna)       Date:  2020-02-18       Impact factor: 3.575

4.  Proteomics analysis of serum protein patterns in duck during aflatoxin B1 exposure.

Authors:  Natthasit Tansakul; Jatuporn Rattanasrisomporn; Sittiruk Roytrakul
Journal:  Vet World       Date:  2019-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.